ZYDUSWELL
ZYDUS WELLNESS LIMITED
Each stock's 10,000-path forecast, rendered as light.
ZYDUS WELLNESS LIMITED (ZYDUSWELL) Stock Analysis & Case Study
Is ZYDUSWELL a good buy? The data-driven verdict.
ZYDUS WELLNESS LIMITED (ZYDUSWELL) trades at ₹537,on the numbers it tread carefully, a Downstox Snapshot Score of 41/100.
On the numbers, ZYDUS WELLNESS LIMITED (ZYDUSWELL) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 73.6× earnings, ROE of 4.0%, a 63% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
ZYDUSWELL fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is ZYDUSWELL overvalued? ZYDUSWELL P/E vs its sector
ZYDUSWELL's P/E of 73.6× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.22% dividend yield is below the peer median of 1.65%.
ZYDUSWELL share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of ZYDUSWELL history (16%/yr drift, 33%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ZYDUSWELL 2027 | ₹376 | ₹574 | ₹875 | +12% |
| ZYDUSWELL 2028 | ₹351 | ₹637 | ₹1,157 | +24% |
| ZYDUSWELL 2029 | ₹343 | ₹716 | ₹1,482 | +40% |
| ZYDUSWELL 2030 | ₹341 | ₹795 | ₹1,850 | +55% |
| ZYDUSWELL 2031 | ₹342 | ₹880 | ₹2,279 | +72% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ZYDUSWELL goes up, or doubles?
The bull case for ZYDUSWELL
- A 10,000-path probability model puts a 63% chance the price is higher in a year, with a median target of ₹574 (+12%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,482.
The bear case & risks
- A rich 73.6× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 4.0%, capital efficiency trails higher-quality peers.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹343.
ZYDUSWELL volatility & expected range, how bumpy is the ride?
Over the last 2.0 years ZYDUSWELL compounded at 16%/year with annualized volatility of 33%. That volatility implies a 1-year 80% range of ₹376–₹875, the honest backbone behind any single price target.
ZYDUSWELL price forecast, the full 60-month probability fan
ZYDUSWELL price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ZYDUSWELL hits common targets within the simulated horizon?
Full multi-horizon detail on the ZYDUSWELL price target & forecast page.
ZYDUSWELL Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. ZYDUSWELL scores 4/9,mixed financial health.
ZYDUSWELL MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy ZYDUSWELL with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 31.6% | 3.2× |
| ZerodhaCHEAPEST | 31.6% | 3.2× |
| DhanCHEAPEST | 31.6% | 3.2× |
Compare every broker on the ZYDUSWELL MTF page.
ZYDUSWELL vs peers,sector comparison
About ZYDUS WELLNESS LIMITED: sector, index & market-cap context
ZYDUS WELLNESS LIMITED (ZYDUSWELL) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹17,076 Cr. See more Nifty 200 stocks.
How the ZYDUSWELL Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of ZYDUS WELLNESS LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ZYDUSWELL analysis, FAQs
Is ZYDUS WELLNESS LIMITED (ZYDUSWELL) a good buy?
On the numbers, ZYDUS WELLNESS LIMITED (ZYDUSWELL) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 73.6× earnings, ROE of 4.0%, a 63% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ZYDUSWELL overvalued or undervalued?
ZYDUSWELL trades at 73.6× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the ZYDUSWELL share price target for 2031?
ZYDUSWELL's probability-weighted 2031 median target is ₹880, with an 80% range of ₹342–₹2,279 (10,000-path Monte-Carlo).
What is the probability ZYDUSWELL doubles in 5 years?
The modelled probability of ZYDUSWELL reaching ₹1,025 (2×) within 5 years is 42%.
What is the bull case for ZYDUSWELL?
A 10,000-path probability model puts a 63% chance the price is higher in a year, with a median target of ₹574 (+12%).
What are the risks in ZYDUSWELL?
A rich 73.6× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 4.0%, capital efficiency trails higher-quality peers.